Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFAN trial
2024-511477-29-00Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of afatinib in Oral Mucosal Carcinoma, oropharyngeal squamous cell carcinoma (OPSCC), squamous cell carcinoma of the hypopharynx and 4 more, sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Objective response rate (ORR) per RECIST v1.1. Planned start Aug 2024; status: authorised.
02
Drugs
afatinib
03
Conditions
Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2024-511477-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511477-29-00.